The Disappearance of SPPI Stock: What Happened?
If you check your brokerage account or popular stock tracking apps today, you might notice that the ticker symbol SPPI (Spectrum Pharmaceuticals, Inc.) has completely vanished. There are no live charts, no daily trading volumes, and no real-time price movements.
This lack of active data has left many retail investors scratching their heads. Did the company go bankrupt? Was it acquired? And what happened to the shares that investors held in their portfolios?
The short answer is that Spectrum Pharmaceuticals was acquired by Assertio Holdings (ASRT) in late 2023. Following the completion of the merger, SPPI stock was officially delisted from the Nasdaq. However, the story didn't end there. Between subsequent corporate acquisitions, failed sales milestones for its flagship drug Rolvedon, and a massive $15.95 million class-action investor settlement, former SPPI shareholders have a lot of moving parts to track.
This guide provides a comprehensive post-merger breakdown of SPPI stock, explaining the conversion mechanics, the final outcome of the Contingent Value Rights (CVRs), and how you might still be eligible to claim a cash payout from recent securities litigation.
The Spectrum-Assertio Merger: Mechanics of the Conversion
On April 25, 2023, Assertio Holdings, Inc. and Spectrum Pharmaceuticals, Inc. announced a definitive merger agreement. Assertio, a specialty pharmaceutical company known for its digital-first, "omni-channel" commercialization strategy, agreed to buy Spectrum in a transaction valued at approximately $248 million upfront.
For Spectrum, a company that was rapidly burning cash and struggling with regulatory hurdles, the buyout was a lifeline. For Assertio, the acquisition was a play to secure Rolvedon (eflapegrastim-xnst), a novel, FDA-approved long-acting injection designed to treat chemotherapy-induced neutropenia (low white blood cell count).
The Key Dates of the Merger
- April 24, 2023: Definitive merger agreement signed.
- July 27, 2023: Spectrum shareholders formally vote and approve the merger at a special meeting.
- July 31, 2023: SPPI stock trades for the last time, halting at 8:00 PM EST after-hours.
- August 1, 2023: The merger officially closes.
- August 2, 2023: SPPI stock is suspended and delisted from the Nasdaq.
How SPPI Shares Were Converted
If you owned SPPI stock at the close of the merger, your broker automatically converted your shares. For every single share of SPPI you owned, you received:
- 0.1783 shares of Assertio Holdings (ASRT) common stock.
- One non-transferable Contingent Value Right (CVR).
At the time of the announcement, the upfront stock consideration was valued at approximately $1.14 per SPPI share, representing a 65% premium to Spectrum's pre-announcement closing price.
If your SPPI holdings did not convert to an exact whole number of ASRT shares, your broker would have credited your account with "cash in lieu of fractional shares."
The Truth About SPPI Contingent Value Rights (CVR): Did They Pay Out?
When the merger closed, many retail investors were highly focused on the Contingent Value Rights (CVRs). In biotech mergers, CVRs are often used as a mechanism to bridge the gap between what an acquirer wants to pay and what target shareholders believe their pipeline is worth.
For SPPI stock holders, the CVRs represented a contractual right to receive up to an additional $0.20 per share (approximately $43 million in aggregate) if certain net sales milestones for Rolvedon were achieved.
The payout structure was broken down as follows:
- Milestone 1: Up to $0.10 per CVR if Rolvedon net sales (minus specific deductions) achieved $175 million during the calendar year ending December 31, 2024.
- Milestone 2: Up to $0.10 per CVR if Rolvedon net sales achieved $225 million during the calendar year ending December 31, 2025.
These payouts were settleable in cash, additional shares of ASRT stock, or a combination of both, at Assertio’s sole discretion.
The Actual Financial Results: Did Rolvedon Hit the Targets?
Unfortunately for former SPPI shareholders, Rolvedon's commercial rollout did not progress as rapidly as initially projected.
According to Assertio's official financial statements:
- In 2024, Rolvedon generated $60 million in net product sales—far below the $175 million milestone required for the first CVR payout.
- In 2025, Rolvedon sales grew slightly to $68 million—again, completely missing the $225 million milestone required for the second CVR payout.
Because Rolvedon’s sales fell short of the contractual thresholds by over 60%, both tiers of the SPPI CVRs expired completely worthless. Shareholders who held onto these digital certificates did not receive any cash or stock payouts from them.
What Happened to the Converted ASRT Shares?
If you held onto the ASRT shares you received from the SPPI stock conversion, the ride was incredibly volatile. Shortly after the merger closed in August 2023, Assertio lost its market exclusivity for its primary revenue-generating drug, Indocin (indomethacin suppositories), due to generic competition from Zydus Lifesciences. This caused ASRT stock to crash by more than 45% in a single day.
However, the corporate saga reached a definitive conclusion in early 2026. On April 8, 2026, Garda Therapeutics announced it had acquired Assertio in a $125.1 million deal ($18.00 per share in cash). This acquisition consolidated Assertio’s specialty oncology assets (primarily Rolvedon) under Garda’s private banner. If you still held ASRT shares in early 2026, they were converted to cash at the buyout price of $18.00 per share when the deal finalized.
The $15.95 Million SPPI Class Action Settlement: Are You Eligible?
While the commercial and corporate outcomes of Spectrum and Assertio left many long-term investors disappointed, there is a major avenue for financial recovery. In May 2025, Spectrum Pharmaceuticals agreed to a $15.95 million cash settlement to resolve a long-standing federal securities fraud class-action lawsuit.
Why Were Investors Suing Spectrum?
The class-action lawsuit (originally filed in late 2021 as International Trading Group, Inc. v. Spectrum Pharmaceuticals, Inc.) alleged that Spectrum and its top executives violated federal securities laws.
Specifically, the plaintiffs argued that Spectrum misled the public about the clinical trial success, safety profile, and regulatory approval prospects of its two primary drug candidates:
- Poziotinib: An investigational tyrosine kinase inhibitor targeted at non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations.
- Rolontis: The initial pre-approval name of the neutropenia drug that would eventually be launched as Rolvedon.
According to the complaint, while Spectrum executives publicly maintained high optimism regarding FDA approval, internal data painted a much darker picture. They allegedly hid disappointing safety and efficacy benchmarks in Poziotinib clinical trials (specifically failures in Cohort 1 and Cohort 3) as well as persistent manufacturing deficiencies at their manufacturing plants.
As these regulatory and clinical failures gradually came to light between 2018 and 2021, SPPI stock lost over 88% of its value, wiping out hundreds of millions in shareholder wealth.
Who Qualifies for the $15.95M Settlement?
You are considered a member of the settlement class if you:
- Purchased or otherwise acquired Spectrum Pharmaceuticals (SPPI) common stock on the open market between March 7, 2018, and August 5, 2021, inclusive, and suffered financial damages.
Payout Expectations
The total settlement fund is $15.95 million. After deducting court-approved attorney fees, administration expenses, and taxes, the remaining "Net Settlement Fund" will be distributed to eligible claimants.
Because payouts are distributed on a pro-rata basis, the exact amount you receive depends on:
- How many shares of SPPI you purchased and sold during the class period.
- The exact timing and prices of those transactions.
- The total number of valid claims submitted.
The claims administrator estimated the average payout to be approximately $0.06 per share before deductions. While this might seem small for individual retail investors who held minor positions, those with thousands of shares stand to recover a meaningful portion of their losses.
Can You Still File a Claim in 2026?
The official deadline to submit a timely Proof of Claim to the administrator was October 1, 2025.
However, there is an important loophole for investors who missed this window: the claims administrator (Verita Global) is still reviewing and accepting late claim submissions.
According to updates from the legal administration of the settlement, late claims may still be approved for a payout as long as the distribution process has not been finalized by the court. If you owned SPPI stock during the specified window (March 2018 – August 2021), you should visit the official Spectrum Pharmaceuticals Securities Settlement website immediately to download, complete, and submit a paper or online Proof of Claim.
The Secondary 2022 SPPI Lawsuit: Christiansen v. Spectrum
If your losses occurred after the August 5, 2021 cutoff for the $15.95M settlement, you are not entirely out of luck. There is a secondary, active securities class-action lawsuit ongoing in the U.S. District Court for the Southern District of New York: Christiansen v. Spectrum Pharmaceuticals, Inc., et al.
The Scope of the 2022 Lawsuit
This lawsuit focuses on a different class period: May 12, 2022, through September 22, 2022.
This action is also centered on poziotinib. The plaintiffs allege that Spectrum continued to issue misleading statements regarding the drug's path to FDA approval. Crucially, the company allegedly failed to disclose to the public that:
- The FDA had expressed severe concerns regarding poziotinib's safety profile and marginal efficacy.
- Spectrum had not enrolled a single patient in its mandatory, confirmatory Phase 3 clinical trial.
These issues exploded into the open in September 2022, when the FDA's Oncologic Drugs Advisory Committee (ODAC) released briefing documents highlighting these massive flaws. Upon this news, SPPI stock crashed by over 37% in a single day, eventually forcing the company to completely abandon the development of poziotinib and lay off 75% of its R&D staff.
Status and Reopening of the Lead Plaintiff Process
In a surprising legal twist, the court disqualified the original lead plaintiff in August 2025 due to allegations of misconduct. As a result, the S.D.N.Y. Court reopened the lead plaintiff process, establishing a deadline of September 24, 2025, for institutional and major retail investors to step forward.
This lawsuit is still actively moving through the discovery and litigation phases in 2026. If you purchased SPPI stock during the mid-2022 window and suffered significant losses, you should keep a close eye on this case, as it may result in a secondary settlement fund in the near future.
Frequently Asked Questions (FAQ) About SPPI Stock
1. Can I still buy or trade SPPI stock today?
No. SPPI stock was officially delisted from the Nasdaq on August 2, 2023, following the merger with Assertio Holdings. The ticker symbol is completely inactive and cannot be purchased or sold on any public exchange.
2. What did I receive for my SPPI stock during the merger?
For each share of SPPI stock you owned at the time of the merger, you received 0.1783 shares of Assertio (ASRT) stock and one non-transferable Contingent Value Right (CVR).
3. Did the SPPI CVRs ever pay out?
No. The CVRs required Rolvedon net sales to reach $175 million in 2024 and $225 million in 2025. Because actual sales reached only $60 million and $68 million respectively, both milestones were missed, and the CVRs expired with zero value.
4. How do I claim my portion of the $15.95 million settlement?
You can submit a claim by visiting the official Spectrum Pharmaceuticals Securities Settlement portal administered by Verita Global. Although the official deadline was October 1, 2025, late claims are currently being accepted on a case-by-case basis. You will need to provide documentation (such as broker statements) showing your SPPI purchases and sales between March 7, 2018, and August 5, 2021.
5. What happened to Assertio (ASRT) stock?
In April 2026, Assertio was acquired by private specialty pharmaceutical company Garda Therapeutics for $125.1 million. Assertio shareholders received $18.00 per share in cash, bringing an end to ASRT's public trading history.
Conclusion: Actionable Next Steps for Former Shareholders
The history of SPPI stock serves as a classic cautionary tale of high-risk biotech investing. While the promise of novel cancer therapies drove intense retail speculation, clinical trial failures, regulatory pushbacks, and slower-than-expected drug rollouts ultimately eroded the company's standalone value.
If you are a former SPPI shareholder, here are the direct actions you should take to manage your historic holdings:
- Check Your Historical Brokerage Statements: Log into your trading platform and look at transactions from late July and early August 2023. Confirm how many shares of SPPI were converted, whether you received ASRT shares, and if you received "cash in lieu" for fractional shares.
- Submit a Late Claim to the Claims Administrator: If you held SPPI stock between March 7, 2018, and August 5, 2021, download the Proof of Claim from the Verita Global settlement website and submit it immediately. Even though it is past the October 2025 deadline, late claims are still being processed.
- Monitor the Christiansen v. Spectrum Lawsuit: If your losses occurred during the mid-2022 window, bookmark updates on the Christiansen case to ensure you don't miss any future claims deadlines or settlement announcements.
